Every 10-Q that AptarGroup, Inc. (ATR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ATR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATR filings page.
AptarGroup, Inc. reported first-quarter 2026 net sales of $982.9 million, up 11% from $887.3 million a year earlier. Foreign exchange and acquisitions drove most of the increase, leaving core sales roughly flat. Net income attributable to AptarGroup was $72.7 million, down from $78.8 million, and diluted EPS declined to $1.12 from $1.17 as margins compressed.
Pharma sales rose to $438.6 million but core sales dipped 1% on lower emergency medicine volumes, while Beauty and Closures delivered modest core growth. Operating margin decreased to 10.9% from 12.8%. Cash flow from operations strengthened to $118.7 million, supporting $65.4 million of capital spending and $100.0 million of share repurchases under a new $600 million authorization.
AptarGroup (ATR) reported higher Q3 2025 revenue and earnings. Net sales rose to $961.1 million from $909.3 million, led by Aptar Pharma ($445.4 million), Beauty ($327.8 million) and Closures ($188.0 million). Operating income was $136.9 million versus $138.3 million a year ago. Other income benefited from a $26.5 million gain from remeasurement of an equity method investment.
Profitability improved year over year. Net income attributable to AptarGroup was $127.9 million (diluted EPS $1.92) versus $100.0 million ($1.48). For nine months, sales reached $2.81 billion with net income of $318.4 million (EPS $4.75) versus $2.73 billion and $273.6 million (EPS $4.05).
Balance sheet and cash flow remained solid. Cash and equivalents were $257.1 million; total assets were $5.10 billion. Net cash provided by operations was $386.3 million. The company used cash for capital expenditures ($183.6 million), treasury stock purchases ($190.0 million) and dividends ($89.3 million). Revolving credit borrowings totaled $187.0 million and €130.0 million under the amended facility. Leverage and coverage remained well within covenants at 1.22x and 17.02x, respectively. Shares outstanding were 65,619,154 as of October 27, 2025.